{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:53Z","timestamp":1793424773288,"version":"4.5.0"},"reference-count":134,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Departamento de Ci\u00eancia e Tecnologia\/Minist\u00e9rio da Sa\u00fade"},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["405733\/2024-0"],"award-info":[{"award-number":["405733\/2024-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["303547\/2023-5"],"award-info":[{"award-number":["303547\/2023-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["380564\/2025-4"],"award-info":[{"award-number":["380564\/2025-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"crossref","award":["APQ-04449-22"],"award-info":[{"award-number":["APQ-04449-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/17425247.2026.2629545","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:38:47Z","timestamp":1770709127000},"page":"841-859","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Intravitreal implants for drug delivery: clinical efficacy, safety, and translational perspectives"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-2487","authenticated-orcid":false,"given":"Carolina Nunes","family":"da Silva","sequence":"first","affiliation":[{"name":"Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-6868","authenticated-orcid":false,"given":"Thomas Toshio","family":"Inoue","sequence":"additional","affiliation":[{"name":"Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-5192","authenticated-orcid":false,"given":"Marina","family":"Fran\u00e7a Dias","sequence":"additional","affiliation":[{"name":"Ezequiel Dias Foundation (FUNED)","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5211","authenticated-orcid":false,"given":"Silvia Ligorio","family":"Fialho","sequence":"additional","affiliation":[{"name":"Ezequiel Dias Foundation (FUNED)","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-8936","authenticated-orcid":false,"given":"Armando","family":"Silva-Cunha","sequence":"additional","affiliation":[{"name":"Federal University of Minas Gerais","place":["Belo Horizonte, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052592"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1240_18"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.9.2653"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02007-4"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0502-y"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-025-00502-9"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S118409"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001188"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-024-01772-x"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03692-7"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.4c01054"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.03.018"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.031"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080140044023"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080140111037"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707103370203"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.02.021"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.9.1191"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.027"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.06.004"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.048"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0100"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.030"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.034"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.01.015"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.125.11.ecs70063"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.001"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.005"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069301"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01830-5"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00446-z"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0006"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0001"},{"key":"e_1_3_6_39_1","unstructured":"Genentech. FDA approves Genentech\u2019s Susvimo as the first and only continuous delivery treatment for retinal disease. Press release; [cited 2025 Feb 4]. [Internet]. Available from: https:\/\/www.gene.com\/media\/press-releases\/15050\/2025-02-04\/fda-approves-genentechs-susvimo-as-the-f"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.024"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-024-00427-9"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-96-6306-4_4"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.339"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6387"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym3031377"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.032"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.021"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.04.011"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003080"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.5.6.615"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20085462"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030930"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-022-00401-z"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1223-2525"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383101"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98568-7"},{"key":"e_1_3_6_58_1","unstructured":"Pieramici DJ. I-vation implant technology. Retinal Physician. 2007 [accessed 2026 Feb 10]. Available form: https:\/\/www.retinalphysician.com\/issues\/2007\/september\/i-vation-implant-technology\/"},{"key":"e_1_3_6_59_1","unstructured":"ClinicalTrials.gov. A study of MK-0140 in diabetic patients with macular edema (NCT00692614) [Internet]. 2015 [accessed 2026 Feb 10].Available from: https:\/\/clinicaltrials.gov\/study\/NCT00692614"},{"issue":"13","key":"e_1_3_6_60_1","first-page":"4332","article-title":"I-vation\u2122 TA: 24-month clinical results of the phase I safety and preliminary efficacy study","volume":"50","author":"Dugel PU","year":"2009","unstructured":"Dugel PU, Eliott D, Cantrill HL, et al. I-vation\u2122 TA: 24-month clinical results of the phase I safety and preliminary efficacy study. Invest Ophthalmol Vis Sci. 2009;50(13):4332. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_61_1","unstructured":"Kuno N Fujii S. Ocular drug delivery systems for the posterior segment: a review. Retina Today. 2012 [accessed 2026 Feb 10]. Available from: https:\/\/retinatoday.com\/articles\/2012-may\/ocular-drug-delivery-systems-for-the-posterior-segment-a-review"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.5497\/wjp.v2.i2.47"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5392"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1063\/5.0264382"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103940"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/app152111599"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11705-014-1442-x"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03848-3"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.126058"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/C2022-0-01672-X"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.14.91"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125822"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2023.11.015"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00945"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070895"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2006.06.009"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081227"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122809"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105413"},{"issue":"7","key":"e_1_3_6_80_1","first-page":"297","article-title":"A safety and pharmacokinetic study of a novel hydrogel-based axitinib intravitreal implant (OTX-TKI) in non-human primates","volume":"63","author":"Kahn E","year":"2022","unstructured":"Kahn E, Patel C, Priem M, et al. A safety and pharmacokinetic study of a novel hydrogel-based axitinib intravitreal implant (OTX-TKI) in non-human primates. Invest Ophthalmol Vis Sci. 2022;63(7):297. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.07.052"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054957"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00316-z"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124700"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125099"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2014.12.003"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.03.001"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1586\/erm.09.15"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1938756"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123973"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124121"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010115"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/20415990.2024.2406226"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2496424"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100527"},{"issue":"7","key":"e_1_3_6_96_1","first-page":"4401","article-title":"The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration","volume":"65","author":"Eichenbaum DA","year":"2024","unstructured":"Eichenbaum DA, Hershberger V, Patel SS, et al. The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration. Invest Ophthalmol Vis Sci. 2024;65(7):4401. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_97_1","unstructured":"EyePoint Pharmaceuticals. EyePoint completes enrollment in pivotal phase 3 LUGANO trial of DURAVYU\u2122 for treatment of wet age-related macular degeneration. 2025 [accessed 2026 Feb 11]. Available from:https:\/\/investors.eyepoint.bio\/news-releases\/news-release-details\/eyepoint-completes-enrollment-pivotal-phase-3-lugano-trial"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2052042"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.12.001"},{"key":"e_1_3_6_100_1","first-page":"251584142110129","article-title":"KSI-301: antibody biopolymer conjugate in retinal disorders","volume":"13","author":"Chandrasekaran PR","year":"2021","unstructured":"Chandrasekaran PR, Madanagopalan VG. KSI-301: antibody biopolymer conjugate in retinal disorders. Ther Adv Ophthalmol. 2021;13:251584142110129.","journal-title":"Ther Adv Ophthalmol"},{"key":"e_1_3_6_101_1","unstructured":"Regillo CD. An antibody biopolymer conjugate for enhanced durability in retinal disease. Retinal Physician. 2020 [accessed 2026 Feb 10]. Available from: https:\/\/www.retinalphysician.com\/issues\/2020\/march\/an-antibody-biopolymer-conjugate-for-enhanced-durability-in-retinal-disease\/"},{"issue":"9","key":"e_1_3_6_102_1","first-page":"3670","article-title":"Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability","volume":"60","author":"Patel SS","year":"2019","unstructured":"Patel SS, Naor J, Qudrat A, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. Invest Ophthalmol Vis Sci. 2019;60(9):3670. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"e_1_3_6_103_1","first-page":"1773","article-title":"Tarcocimab tedromer (KSI-301) 5 mg: outcomes of the phase 3 GLOW study in patients with nonproliferative diabetic retinopathy","volume":"65","author":"Wong RW","year":"2024","unstructured":"Wong RW, Janer D, Zawadzki R, et al. Tarcocimab tedromer (KSI-301) 5 mg: outcomes of the phase 3 GLOW study in patients with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2024;65(7):1773. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"e_1_3_6_104_1","first-page":"2215","article-title":"Biological benefits of KSI-501: novel bispecific anti-inflammatory and anti-angiogenic therapy for the treatment of retinal vascular and inflammatory diseases","volume":"64","author":"Williams K","year":"2023","unstructured":"Williams K, Rodriguez M, Fischer WN, et al. Biological benefits of KSI-501: novel bispecific anti-inflammatory and anti-angiogenic therapy for the treatment of retinal vascular and inflammatory diseases. Invest Ophthalmol Vis Sci. 2023;64(8):2215. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"e_1_3_6_105_1","first-page":"936","article-title":"US phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration","volume":"64","author":"Moshfeghi AA","year":"2023","unstructured":"Moshfeghi AA, Khanani AM, Eichenbaum DA, et al. US phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64(8):936. Abstract.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_106_1","unstructured":"Ocular Therapeutix. Ocular Therapeutix announces first patients enrolled in phase 3 SOL-R wet AMD study evaluating repeat AXPAXLI\u2122 dosing for wet age-related macular degeneration. 2024."},{"key":"e_1_3_6_107_1","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration (NCT06223958). 2025 [accessed 2026 Feb 10].Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06223958"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000413"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713680600719036"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00787-5"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2017.1391820"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.09.041"},{"key":"e_1_3_6_113_1","unstructured":"U.S. Food and Drug Administration. ENCELTO. 2025 [accessed 2026 Feb 11]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/center-biologics-evaluation-and-research-cber-product-approval-information\/encelto"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.891"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2536420"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23810"},{"key":"e_1_3_6_117_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Quality considerations for topical ophthalmic drug products: guidance for industry (draft). 2023 [accessed 2026 Feb 10]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quality-considerations-topical-ophthalmic-drug-products"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2006.07.027"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061746"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125453"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.787644"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125959"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.12.008"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000001017"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1177\/17411343251313962"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00397-017-0997-0"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01043-z"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091394"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100125"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030786"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13480"},{"key":"e_1_3_6_132_1","unstructured":"US Food and Drug Administration. Current good manufacturing practice requirements for combination products. 2017 [accessed 2026 Feb 10]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-requirements-combination-products"},{"key":"e_1_3_6_133_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.2c00793"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.0c00412"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-025-00838-3"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.3441"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2629545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:57:09Z","timestamp":1777903029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2629545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/17425247.2026.2629545"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2629545","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}